CY1122949T1 - ΠΥΡΑΖΟΛΟ[1,5-a]ΠΥΡΑΖΙΝ-4-ΥΛΟ ΠΑΡΑΓΩΓΑ ΩΣ JAK-ΑΝΑΣΤΟΛΕΙΣ - Google Patents

ΠΥΡΑΖΟΛΟ[1,5-a]ΠΥΡΑΖΙΝ-4-ΥΛΟ ΠΑΡΑΓΩΓΑ ΩΣ JAK-ΑΝΑΣΤΟΛΕΙΣ

Info

Publication number
CY1122949T1
CY1122949T1 CY20201100470T CY201100470T CY1122949T1 CY 1122949 T1 CY1122949 T1 CY 1122949T1 CY 20201100470 T CY20201100470 T CY 20201100470T CY 201100470 T CY201100470 T CY 201100470T CY 1122949 T1 CY1122949 T1 CY 1122949T1
Authority
CY
Cyprus
Prior art keywords
alkyl
hydroxy
independently
cycloalkyl
heteroaryl
Prior art date
Application number
CY20201100470T
Other languages
English (en)
Inventor
Matthew Frank Brown
Alpay Dermenci
Andrew Fensome
Brian Stephen Gerstenberger
Matthew Merrill Hayward
Stephen Wayne Wright
Li Huang XING
Xiaojing Yang
Dafydd Rhys Owen
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of CY1122949T1 publication Critical patent/CY1122949T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Μία ένωση η οποία έχει τη δομή (Ι) ή ένα φαρμακευτικώς αποδεκτό άλας αυτής, ή ένα φαρμακευτικώς αποδεκτό επιδιαλύτωμα της εν λόγω ένωσης ή φαρμακευτικώς αποδεκτού άλατος, όπου Α, Α' και Α" είναι ανεξάρτητα Ο, C=O, C-R' ή N-R", όπου R' και R" μπορεί ανεξάρτητα να είναι Η, αμινο, -NR7COR6, COR6, -CONR7R8, C1-C6 αλκύλιο, ή υδροξυ(C1-C6 αλκύλιο), και R" μπορεί να υπάρχει ή να απουσιάζει, και υπάρχει όπου οι κανόνες του σθένους το επιτρέπουν, και όπου όχι περισσότερα από ένα από Α, Α' και Α" είναι Ο ή C=O· R0 και R είναι ανεξάρτητα Η, Br, Cl, F ή C1-C6 αλκύλιο· R1 είναι Η, C1-C6 αλκύλιο, ή υδροξυ(C1-C6 αλκύλιο)· R2 επιλέγεται από την ομάδα η οποία αποτελείται από Η, C1-C6 αλκύλιο, C1-C6 αλκοξυ, υδροξυ(C1-C6 αλκύλιο), φαινυλο(C1-C6 αλκύλιο), φορμύλιο, ετεροαρύλιο, ετεροκυκλικό, -COR6, - OCOR6, -COOR6, -NR7COR6, -CONR7R8 και -(CH2)n-W, όπου W είναι κυανό, υδροξυ, C3-C8 κυκλοαλκύλιο, -SO2NR7R8 και -SO2-R9, όπου R9 είναι C1-C6 αλκύλιο, C3-C8 κυκλοαλκύλιο, ετεροαρύλιο ή ετεροκυκλικό· όπου κάθε ένα από το εν λόγω αλκύλιο, κυκλοαλκύλιο, ετεροκυκλικό ή ετεροαρύλιο μπορεί να είναι μη-υποκατεστημένο ή υποκατεστημένο με αλογόνο, κυανό, υδροξυ ή C1-C6 αλκύλιο· Χ είναι C-R3 ή Ν, όπου R3 μπορεί να είναι Η ή C1-C6 αλκύλιο· R4 και R5 είναι ανεξάρτητα Η, αμινο, C1-C6 αλκύλιο, ή υδροξυ(C1-C6 αλκύλιο)· R6, R7 και R8 είναι το καθένα ανεξάρτητα Η, C1-C6 αλκύλιο, C1-C4 αλκοξυ(C1-C6 αλκύλιο), ή C3-C8 κυκλοαλκύλιο, με το εν λόγω C1-C6 αλκύλιο να είναι προαιρετικά υποκατεστημένο με αλογόνο, CN ή υδροξυ· ή, R7 και R8 μαζί με το άτομο το οποίο είναι ενωμένο με αυτά σχηματίζουν έναν 5- ή 6-μελή δακτύλιο, με τον εν λόγω δακτύλιο να είναι προαιρετικά υποκατεστημένος με αλογόνο, υδρoξυ, CN, ή C1- C6 αλκύλιο· και, n είναι 0, 1, 2 ή 3. Παρέχονται επίσης μέθοδοι αγωγής ως αναστολείς Janus Κινασών και φαρμακευτικές συνθέσεις οι οποίες περιέχουν τις ενώσεις της εφεύρεσης και συνδυασμούς αυτών με άλλους θεραπευτικούς παράγοντες.
CY20201100470T 2016-02-24 2020-05-15 ΠΥΡΑΖΟΛΟ[1,5-a]ΠΥΡΑΖΙΝ-4-ΥΛΟ ΠΑΡΑΓΩΓΑ ΩΣ JAK-ΑΝΑΣΤΟΛΕΙΣ CY1122949T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662299130P 2016-02-24 2016-02-24
PCT/IB2017/050748 WO2017144995A1 (en) 2016-02-24 2017-02-10 Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors

Publications (1)

Publication Number Publication Date
CY1122949T1 true CY1122949T1 (el) 2021-10-29

Family

ID=58054385

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100470T CY1122949T1 (el) 2016-02-24 2020-05-15 ΠΥΡΑΖΟΛΟ[1,5-a]ΠΥΡΑΖΙΝ-4-ΥΛΟ ΠΑΡΑΓΩΓΑ ΩΣ JAK-ΑΝΑΣΤΟΛΕΙΣ

Country Status (45)

Country Link
US (4) US10144738B2 (el)
EP (2) EP3712153B1 (el)
JP (1) JP6505956B2 (el)
KR (1) KR102128671B1 (el)
CN (1) CN109071546B (el)
AR (1) AR107714A1 (el)
AU (1) AU2017222417B2 (el)
CA (1) CA2958490C (el)
CL (1) CL2018002358A1 (el)
CO (1) CO2018008799A2 (el)
CR (1) CR20180372A (el)
CU (1) CU24511B1 (el)
CY (1) CY1122949T1 (el)
DK (1) DK3419978T3 (el)
DO (1) DOP2018000187A (el)
EA (1) EA035036B1 (el)
EC (1) ECSP18072109A (el)
ES (1) ES2794779T3 (el)
GE (1) GEP20217242B (el)
HK (1) HK1258157A1 (el)
HR (1) HRP20200781T1 (el)
HU (1) HUE049305T2 (el)
IL (1) IL260923B (el)
LT (1) LT3419978T (el)
MA (2) MA52987A (el)
MD (1) MD3419978T2 (el)
ME (1) ME03743B (el)
MX (1) MX2018010236A (el)
MY (1) MY189118A (el)
NI (1) NI201800080A (el)
NZ (1) NZ744349A (el)
PH (1) PH12018501788A1 (el)
PL (1) PL3419978T3 (el)
PT (1) PT3419978T (el)
RS (1) RS60261B1 (el)
RU (1) RU2718902C2 (el)
SG (1) SG11201806307YA (el)
SI (1) SI3419978T1 (el)
SV (1) SV2018005726A (el)
TN (1) TN2018000295A1 (el)
TW (1) TWI665201B (el)
UA (1) UA119835C2 (el)
UY (1) UY37133A (el)
WO (1) WO2017144995A1 (el)
ZA (1) ZA201804972B (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071546B (zh) 2016-02-24 2021-03-02 辉瑞大药厂 作为jak抑制剂的吡唑并[1,5-a]吡嗪-4-基衍生物
IL303087B1 (en) 2018-02-27 2024-08-01 Incyte Corp Midazopyrimidines and triazolopyrimidines as A2A /A2B inhibitors
US10508113B2 (en) 2018-03-12 2019-12-17 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
EA202092779A1 (ru) 2018-05-17 2021-02-02 Байер Акциенгезельшафт Замещенные дигидропиразолопиразинкарбоксамидные производные
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
CN113166153A (zh) 2018-07-05 2021-07-23 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
AR116592A1 (es) 2018-10-17 2021-05-26 Lilly Co Eli Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
JP7256291B2 (ja) * 2019-04-12 2023-04-11 プライムジーン(ベイジン)カンパニー リミテッド ピラゾロピラジン誘導の化合物、医薬組成物およびその使用
JP2022537877A (ja) 2019-04-30 2022-08-31 セルジーン コーポレイション アプレミラストおよびtyk2阻害剤を含む併用療法
CN114667148A (zh) * 2019-09-11 2022-06-24 辉瑞公司 用jak抑制剂治疗汗腺炎
TW202135816A (zh) * 2019-12-18 2021-10-01 美商輝瑞股份有限公司 以激酶抑制劑治療潰瘍性結腸炎
AU2021248720A1 (en) 2020-04-04 2022-11-03 Pfizer Inc. Methods of treating coronavirus disease 2019
US20230159539A1 (en) * 2020-04-08 2023-05-25 Pfizer Inc. Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof
JP2023542298A (ja) * 2020-09-11 2023-10-06 プルモシム セラピューティクス リミテッド ライアビリティ カンパニー 肺高血圧症を治療又は予防する組成物及び方法
CN112592345B (zh) * 2020-12-07 2024-09-13 嘉兴特科罗生物科技有限公司 一种三氮唑并吡嗪类化合物及其用途
WO2022165530A1 (en) * 2021-02-01 2022-08-04 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
WO2022208315A1 (en) 2021-03-30 2022-10-06 Pfizer Inc. Methods for treatment of vitiligo
AU2022378463A1 (en) 2021-10-25 2024-05-09 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
TWI839945B (zh) * 2021-11-12 2024-04-21 大陸商南京明德新藥研發有限公司 吡唑並環化合物及其應用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114941B1 (en) 2006-12-22 2015-03-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
AR066879A1 (es) * 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
RS54560B1 (en) 2008-06-10 2016-06-30 Abbvie Inc. TRICYCLIC UNITS
ES2378513T3 (es) 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
WO2010117787A2 (en) 2009-03-30 2010-10-14 The Brigham And Women's Hospital, Inc. Inhibiting eph b-3 kinase
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
AU2011240808B2 (en) * 2010-04-14 2015-01-22 Array Biopharma Inc. 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of JAK kinases
EP2397482A1 (en) 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
WO2013055645A1 (en) 2011-10-12 2013-04-18 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
US9187453B2 (en) * 2012-03-28 2015-11-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN104169284B (zh) 2012-03-28 2017-03-29 默克专利股份公司 双环吡嗪酮衍生物
US9376441B2 (en) 2013-07-31 2016-06-28 Gilead Sciences, Inc. Substituted pyrrolidines as SYK inhibitors
TW201605811A (zh) 2013-12-11 2016-02-16 阿爾米雷爾有限公司 作為jak抑制劑之吡唑并嘧啶-2基衍生物
EP3137454A1 (en) * 2014-04-28 2017-03-08 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
WO2016009028A1 (fr) 2014-07-17 2016-01-21 Valeo Systèmes d'Essuyage Balai plat caréné d'essuie-glace
PT3227297T (pt) * 2014-12-05 2021-04-09 Array Biopharma Inc Pirazol[1,5-a]pirazinas, substituídas nas posições 4 e 6, como inibidores de cinases janus
TW201639845A (zh) 2015-01-29 2016-11-16 和記黃埔醫藥(上海)有限公司 新的雜芳基和雜環化合物、其組成物及方法
CN107801397B (zh) 2015-02-13 2021-07-30 达纳-法伯癌症研究所公司 Lrrk2抑制剂及其制备和使用方法
GB201504565D0 (en) 2015-03-18 2015-05-06 Takeda Pharmaceutical Novel compounds
ES2734048T3 (es) 2015-04-29 2019-12-04 Wuxi Fortune Pharmaceutical Co Ltd Inhibidores de Janus cinasas (JAK)
CN108473498B (zh) 2015-12-22 2021-11-02 豪夫迈·罗氏有限公司 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
CN109071546B (zh) 2016-02-24 2021-03-02 辉瑞大药厂 作为jak抑制剂的吡唑并[1,5-a]吡嗪-4-基衍生物
EP3558991A2 (en) 2016-12-23 2019-10-30 Plexxikon Inc. Compounds and methods for cdk8 modulation and indications therefor
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
CN110785418A (zh) 2017-06-21 2020-02-11 豪夫迈·罗氏有限公司 作为irak4调节剂的异二氢吲哚酮衍生物
WO2019034973A1 (en) 2017-08-14 2019-02-21 Pfizer Inc. PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES

Also Published As

Publication number Publication date
HK1258157A1 (zh) 2019-11-08
DK3419978T3 (da) 2020-06-02
MA43668B1 (fr) 2020-05-29
EP3712153A1 (en) 2020-09-23
US20190071448A1 (en) 2019-03-07
HRP20200781T1 (hr) 2020-07-24
CO2018008799A2 (es) 2018-09-20
PT3419978T (pt) 2020-06-01
TN2018000295A1 (en) 2020-01-16
TW201741313A (zh) 2017-12-01
US20230045252A1 (en) 2023-02-09
UY37133A (es) 2017-09-29
UA119835C2 (uk) 2019-08-12
ES2794779T3 (es) 2020-11-19
US10822341B2 (en) 2020-11-03
NZ744349A (en) 2023-06-30
EP3419978B1 (en) 2020-04-15
GEP20217242B (en) 2021-04-12
RU2718902C2 (ru) 2020-04-15
PL3419978T3 (pl) 2020-11-30
EP3419978A1 (en) 2019-01-02
TWI665201B (zh) 2019-07-11
MX2018010236A (es) 2019-01-14
LT3419978T (lt) 2020-06-10
CU24511B1 (es) 2021-05-12
US20200399281A1 (en) 2020-12-24
SG11201806307YA (en) 2018-09-27
HUE049305T2 (hu) 2020-09-28
SV2018005726A (es) 2018-10-24
KR20180103158A (ko) 2018-09-18
ECSP18072109A (es) 2018-10-31
EP3712153B1 (en) 2021-12-01
CA2958490C (en) 2024-02-27
JP6505956B2 (ja) 2019-04-24
KR102128671B1 (ko) 2020-06-30
RS60261B1 (sr) 2020-06-30
IL260923B (en) 2022-01-01
WO2017144995A1 (en) 2017-08-31
CN109071546A (zh) 2018-12-21
ME03743B (me) 2021-04-20
NI201800080A (es) 2018-11-22
AR107714A1 (es) 2018-05-23
SI3419978T1 (sl) 2020-08-31
DOP2018000187A (es) 2019-01-31
CA2958490A1 (en) 2017-08-24
MA52987A (fr) 2021-04-28
JP2019510003A (ja) 2019-04-11
AU2017222417B2 (en) 2020-07-09
PH12018501788A1 (en) 2019-06-17
AU2017222417A1 (en) 2018-08-02
RU2018130547A (ru) 2020-03-25
MD3419978T2 (ro) 2020-07-31
EA201891463A1 (ru) 2019-03-29
US10144738B2 (en) 2018-12-04
CN109071546B (zh) 2021-03-02
EA035036B1 (ru) 2020-04-20
RU2018130547A3 (el) 2020-03-25
CR20180372A (es) 2018-09-19
BR112018015501A2 (pt) 2018-12-18
US20170240552A1 (en) 2017-08-24
MY189118A (en) 2022-01-26
CL2018002358A1 (es) 2018-11-30
CU20180078A7 (es) 2019-02-04
US11472809B2 (en) 2022-10-18
ZA201804972B (en) 2019-06-26

Similar Documents

Publication Publication Date Title
CY1122949T1 (el) ΠΥΡΑΖΟΛΟ[1,5-a]ΠΥΡΑΖΙΝ-4-ΥΛΟ ΠΑΡΑΓΩΓΑ ΩΣ JAK-ΑΝΑΣΤΟΛΕΙΣ
CY1124478T1 (el) Ετεροκυκλικες ενωσεις ως αναστολεις της κiνασης ret
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA201992884A2 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
EA202192019A1 (ru) Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения
AR096846A1 (es) Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
AR115871A1 (es) MÉTODO PARA CONTROLAR EL HONGO DE LA ROYA DE LA SOJA QUE TIENE RESISTENCIA AL INHIBIDOR DE SITIO Qₒ
CL2021002165A1 (es) Nuevos derivados de compuestos heterociclicos y uso de los mismos
PE20231311A1 (es) Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos
EA202091475A1 (ru) ПРОИЗВОДНЫЕ 5-(2-(2,5-ДИФТОРФЕНИЛ)ПИРРОЛИДИН-1-ИЛ)-3-(1H-ПИРАЗОЛ-1-ИЛ)ПИРАЗОЛО[1,5-а]ПИРИМИДИНА И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
EA201791816A1 (ru) Ингибиторы kv1.3 и их применение в медицине
PE20181017A1 (es) Compuestos heteroarilo y su uso como farmacos terapeuticos
EA201992771A1 (ru) Ингибитор поверхностного антигена вируса гепатита b
BR112022001922A2 (pt) Compostos de heteroarila de anel fundido como inibidores de ripk1
EA202091692A1 (ru) Амидинзамещенные бензоильные производные, пригодные в качестве гербицидов
AR083832A1 (es) DERIVADOS DE TETRAHIDROPIRIDO[3,2-F][1,4]OXAZEPIN-8-AMINA PARA EL TRATAMIENTO DE ENFERMEDADES Ab-RELACIONADAS
PE20190735A1 (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
EA202192760A1 (ru) Трициклические соединения
EA202190322A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ TRK
EA201792087A1 (ru) ПРОИЗВОДНЫЕ 7-(МОРФОЛИН-4-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИМИДИНА, ПРИГОДНЫЕ ДЛЯ ЛЕЧЕНИЯ ИММУННЫХ ИЛИ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ИЛИ РАКА
BRPI0510075A (pt) benzoxazocinas e seu uso terapêutico como inibidores de reabsorção de monoamina
EA201791817A1 (ru) Ингибиторы kv1.3 и их применение в медицине